Patents by Inventor James Legg

James Legg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding Constructs
    Publication number: 20260176336
    Abstract: The invention provides inter alia a construct comprising a FAP binding agent and an LTBR binding agent.
    Type: Application
    Filed: February 26, 2026
    Publication date: June 25, 2026
    Inventors: Ray Jupp, James Legg, Fevzi Demircioglu, Marta Lewandowska, Lucy Penfold, Bruno Dombrecht
  • THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1
    Publication number: 20240350651
    Abstract: The invention relates to LAG-3 binding agents, in particular particularly variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: March 13, 2024
    Publication date: October 24, 2024
    Inventors: Carolyn EDWARDS, Angelica SETTE, Isabelle OSUCH, Yumin TENG, James LEGG, David ESCORS MURUGARREN
  • Single domain antibodies that bind to CD137
    Patent number: 12077595
    Abstract: The disclosure relates to CD137 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: September 3, 2024
    Assignee: Crescendo Biologics Limited
    Inventors: Verena Brucklacher-Waldert, Carolyn Edwards, James Legg, Jayesh Majithiya, Brian McGuinness, Christine Rossant, Yumin Teng
  • Therapeutic molecules that bind to LAG3 and PD1
    Patent number: 11951172
    Abstract: The invention relates to LAG-3 binding agents, in particular variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, Angelica Sette, Isabelle Osuch, Yumin Teng, James Legg, David Escors Murugarren
  • Single domain antibodies to programmed cell death (PD-1)
    Patent number: 11814429
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 14, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
    Publication number: 20230357405
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 9, 2023
    Inventors: Phil HAYES, James LEGG, Martyna LEWANDOWSKA, Colette Johnston, Brian McGUINNESS, Mike ROMANOS, Christine ROSSANT, Yumin TENG
  • Single domain antibodies to programmed cell death protein 1 (PD-1)
    Patent number: 11591398
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: February 28, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20220306744
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 29, 2022
    Inventors: Carolyn EDWARDS, James LEGG, Martyna LEWANDOWSKA, Colette JOHNSTON, Christine ROSSANT, Yumin TENG
  • BINDING MOLECULES
    Publication number: 20220220215
    Abstract: The disclosure relates to multispecific agents that simultaneously bind CD137 and PD-1 and which comprise a single domain antibody specific to CD137 and a moiety that binds PD-1, for example a single domain antibody. The disclosure also relates to therapeutic and diagnostic applications of such agents, for example in the treatment of a cancer.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 14, 2022
    Inventors: Carrie ENEVER, Colette JOHNSTON, James LEGG, Pavel PISA, Martyna LEWANDOWSKA, Iain SCOTT
  • Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
    Patent number: 11312771
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 26, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1
    Publication number: 20210015937
    Abstract: The invention relates to LAG-3 binding agents, in particular particularly variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: February 18, 2019
    Publication date: January 21, 2021
    Inventors: Carolyn EDWARDS, Angelica SETTE, Isabelle OSUCH, Yumin TENG, James LEGG, David ESCORS MURUGARREN
  • SINGLE DOMAIN ANTIBODIES THAT BIND TO CD137
    Publication number: 20200362047
    Abstract: The disclosure relates to CD137 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: November 13, 2018
    Publication date: November 19, 2020
    Inventors: Verena BRUCKLACHER-WALDERT, Carolyn EDWARDS, James LEGG, Jayesh MAJITHIYA, Brian MCGUINNESS, Christine ROSSANT, Yumin TENG
  • MOLECULES THAT BIND TO CD137 AND PSMA
    Publication number: 20200362051
    Abstract: The disclosure relates to agents that simultaneously bind CD137 and PSMA and which comprise a single domain antibody specific to CD137 and a moiety that binds PSMA. The disclosure also relates to therapeutic and diagnostic applications of such agents, for example in the treatment or detection of a cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: November 19, 2020
    Inventors: Verena BRUCKLACHER-WALDERT, Carolyn EDWARDS, James LEGG, Jayesh MAJITHIYA, Christine ROSSANT
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239573
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239570
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20190322749
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: October 24, 2019
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng